GenSight Biologics to Attend Chardan Gene Therapy Conference

GenSight Biologics integrates the Enternext® PEA-PME 150 index

GenSight Biologics integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext indexes

GenSight Biologics Reports Interim Financial Results for the First Half of 2017

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

GenSight Biologics launches a capital increase of approximately €20 million

GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer

GenSight Biologics Announces the Filing of its 2016 Registration Document

GenSight Biologics to Attend Upcoming Investor Conferences

GenSight Biologics Reports Full Year 2016 Financial Results